Concepedia

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, R. Shah, Mary O’Brien, A. Pope, P.M. Fisher, James Spicer, A. Roy, David Gilligan,

Annals of Oncology · 2020 · 273 citations · 18 references

DOIFull text

Open access

Concepts

References

18

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

, , +15

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3.1K citations

, , +13

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 972 citations

, , +10

Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests

James M. Robins, Dianne M. Finkelstein · Biometrics · 2000 · 860 citations

, , +17

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold et al. · Journal of Clinical Oncology · 2005 · 621 citations · Full text

, , +14